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These comments were delivered upon receiving the Lillian
Jean Kaplan International Prize for Advancement in the
Understanding of Polycystic Kidney Disease at the World
Congress of Nephrology in Berlin, Germany, June 9, 2003.
Understanding polycystic kidney disease: A systems biology
approach.
Fluid secretion was discovered in the mammalian nephron
in the early 1970s upon a chance observation. This finding
aroused interest in the possibility that a similar process might
be involved in the filling of renal epithelial cysts. A research
strategy was formulated to understand the life cycle of human
renal cysts using a systems biology approach. A not-for-profit
foundation was begun to increase the number of researchers
in the United States and abroad working on the polycystic
kidney disease (PKD) problem.
Primary outcomes related to PKD include (1) explication
of the transport mechanisms underlying the transepithelial se-
cretion of chloride, sodium and fluid, and the regulation of
that secretion by cyclic adenosine monophosphate (AMP); (2)
the discovery that cyclic AMP stimulates the proliferation of
cyst epithelial cells through activation of of B-Raf and the
mitogen-activated protein (MAP) kinase pathway; and (3) the
discovery that normal medullary collecting ducts secrete solutes
and fluid under the control of cyclic AMP.
The Polycystic Kidney Disease Foundation has become an
international leader in promoting the research of these disor-
ders and is a strong advocate for increased translation of funda-
mental laboratory discoveries to the care of the millions of
patients with PKD.
I want to thank the Lillian Jean Kaplan Foundation,
and especially Mr. Thomas Kaplan, for creating this
award to enhance the understanding of polycystic kidney
disease (PKD). I am deeply honored and most grateful
to be one of the inaugural recipients of this award.
I also want to thank the International Society of Ne-
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tin, autosomal-dominant PKD.
 2003 by the International Society of Nephrology
1157
phrology and the Polycystic Kidney Disease Foundation
for their respective roles in making this moment happen.
This is a celebration, indeed, not just for me and my
colleagues, but for the beginning of a scientific thrust
toward solving one pernicious health problem harbored
in our DNA.
Mutations are what make us different from one an-
other. And unfortunately, being human means that many
of us carry altered DNA that could become an undesired
signature of our family tree for centuries to come. A
striking example of a malicious genetic disorder that
nephrologists know well, PKD affects the lives of mil-
lions and millions of individuals on every continent in
the world. The kidneys enlarge several times greater
than normal, and, by virtue of size alone, can cause
severe, painful symptoms that diminish the quality of
life. Renal failure develops in more than 50% of patients
and is one of the most feared complications of PKD.
But, despite the prevalence and the severity of PKD, it
was largely ignored by the scientific community and the
lay public until a small group of scientists banded to-
gether in 1982 with Joseph Bruening, a Kansas City busi-
nessman, to develop a plan of attack [1].
Today, the Lillian Jean Kaplan prizes celebrate proof
that the understanding of PKD has improved and will
continue to improve rapidly. When I conclude with my
remarks, I trust that you will agree that PKD research
is on the cutting edge of scientific discovery, perhaps
even serving as a paradigm for the exploration of a host
of other disorders that destroy kidney function.
THE JOURNEY BEGINS
I was drawn to the research of PKD by two powerful
forces, one emotional and the other scientific. My best
friend in elementary school, Ronnie Wilkerson, and his
mother had PKD. Ronnie explained to me when we
were youngsters that he had a fatal illness, and that
one day he would die of kidney failure. As forecast, his
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Fig. 1. Method for demonstrating that proxi-
mal straight tubules change from absorbing
to secreting fluid when para-aminohippurate
(PAH) is added to the external bath. Secretion
was confirmed by showing that the addition
of PAH to the bath caused the lumens of
nonperfused proximal straight tubules to dis-
tend with fluid.
mother died in her forties, but Ronnie was luckier as
he survived long enough to benefit from hemodialysis,
although he was never lucky enough to get a viable
kidney transplant, despite two failed attempts.
While Ronnie struggled with PKD, I went on to col-
lege, medical school, and research training, landing back
at the University of Kansas in 1969, where I introduced
the brand new isolated, perfused tubule technique I had
worked on with Maurice Burg at the National Institutes
of Health. I made a surprising discovery in my research
laboratory quite by chance. I was studying the absorption
of salt and fluid from isolated perfused proximal straight
tubules of rabbits at the time and had found that certain
diuretics seemed to inhibit fluid absorption. To make
the measurement of net fluid transport easier, I had
devised an unusual way to quantify absorption, as illus-
trated in the upper panel of Figure 1.
One end of the tubule was cannulated with a perfusion
pipette and the other was crimped shut. I placed a small
droplet of oil within the lumen of the perfusion pipette
so that fluid moving out of the pipette and into the tubule
lumen could be quantified by simply measuring the dis-
tance the oil drop moved along the pipette. Since the
other end of the tubule was crimped shut, the only way
that fluid could leave the pipette was if it was absorbed by
the tubule epithelium. Normally, these tubule segments
absorb fluid and solutes by a mechanism that depends
on the active transport of sodium. But unwittingly, my
device for measuring absorption had reproduced the
same properties found in a tiny, early-stage renal cyst.
In a telephone discussion with Maurice “Moe” Burg,
that I can only regard as providential, we talked about
these diuretic experiments. Moe, who possesses one of
the greatest analytical minds I have ever known, won-
dered if the effects of the diuretics I had been examining
were perhaps due to the accumulation of poorly reab-
sorbed solutes within the stationary perfused tubules.
Proximal straight tubules actively secrete most diuretics
so his was a reasonable concern.
To check that out, I used as a control a chemical, para-
aminohippurate (PAH), that was secreted into the urine
of proximal tubules to levels several-fold higher than in
the peritubular medium. I figured that if that stuff did
not work, I would not have to worry about Moe’s con-
cern. Patti Qualizza, my research assistant at the time,
and I were surprised, or perhaps a better word is shocked,
when we saw the oil drop move backward, up that inner
pipette after we had added PAH to the external bath.
PAH had completely reversed the absorption of solute
and fluid by the tubule, something I had been led to
believe at the time should not happen in the mighty
nephron. Good grief, we had just made water run uphill,
literally [2–4]!
Fearing that we had observed a career-ending artifact,
we studied some proximal straight tubules that had not
been perfused in vitro. As shown in the lower panel of
Figure 1, we obtained additional evidence that fluid was,
indeed, secreted by the tubule segment when PAH
caused the lumen to open and become distended within
a few minutes.
As most of you have been taught, respectable mamma-
lian renal tubules are supposed to reabsorb glomerular
filtrate, removing all but a tiny fraction to be excreted
as urine. We filter approximately 180 L of plasma each
day, and the tubules reabsorb all but about 1.5 L, leaving
less than 1% of the filtered plasma to escape the kidneys
as urine. Reabsorption takes place primarily in the proxi-
mal tubules, loop of Henle, and distal convoluted tu-
bules, leaving only a small amount of reabsorption to be
done by the collecting duct system.
And here I was about to tell the world that I had
converted our sacred nephron into the equivalent of a
tear duct, a sweat duct, or even worse, a gut.
But that is when my friend Ronnie Wilkerson came
to my rescue. Within days of discovering net fluid secre-
tion, it occurred to me that Ronnie’s renal cysts might
utilize a secretion mechanism to fill them with fluid. I
could hide this new phenomenon we had discovered
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behind the pathology of renal cystic disease. So, with
this stealth hypothesis before me, I began a journey into
renal cystic disease that has brought me here today.
We have known since Dalgaard’s description of the
clinical genetics that autosomal-dominant PKD (AD-
PKD) must be caused by a defect in DNA [5]. The
problem was, when I entered this field of study in the
1970s, there were no practical tools one could use to
study DNA in a hereditary disease. Linkage analysis was
just an idea and DNA sequencing a nightmarish, and
often futile exercise. So where should I start?
Without any coaching, I chose to use what is recog-
nized today as a “systems biology” approach. In this
approach, one examines the full context of the problem,
including etiology, organ and tissue structure, and molec-
ular composition in the context of the relevant integrated
function or, in the case of PKD, dysfunction. Systems
biology is contrasted with the currently popular bits-and-
pieces-approaches, molecular biology, and proteomics,
in which careers are built upon a novel gene or protein
that may pop out of a genomic or proteomic array. As
a systems biologist, I started searching for an understand-
ing of PKD before we had the exact cause in hand, the
mutated molecules.
At the time, scientists in the 20th century had not
looked very carefully at the disease, with the exception
of O.Z. Dalgaard [5], Luc Baert [6], Kenneth Gardner
[7], Frank Carone [8], Andrew Evan [9], and Jay Bern-
stein [10]. A newcomer to this small field, it took me
about a day to catch up with the literature and to figure
out that some relatively simple studies to redefine the
anatomic structure of the cystic kidney had to be done.
So I initiated some descriptive experiments with a view
to understanding the life cycle of a renal cyst.
My colleagues and I confirmed Gardner’s finding in
human ADPKD that cysts are in fact remnants of func-
tioning renal tubules that have expanded in some cases
to thousands of times greater than normal size [11–13].
We provided quantitative proof for the suggestion by
Evan and Bernstein that proliferation of mural epithelial
cells was responsible for the expansion of the cysts [14].
And we also confirmed Carone’s discovery that the tu-
bule basement membranes are involved in a remodeling
process in association with interstitial fibrosis [11].
To this, we added some new findings and insights. In
our electron microscope studies, it became clear that
cysts develop in only a tiny fraction of the renal tubules
at risk [14]. Empirical examination of CT and MRI scans
of patients with ADPKD indicated that renal cysts did
not necessarily become more numerous as these patients
grew older, but that established cysts certainly got larger
[15]. In the early stages of the disease, when the disorder
usually went clinically unrecognized, renal cysts ap-
peared few and separated by fields of normal paren-
chyma. It was usually later, when the individual cysts
grew larger and the parenchyma was replaced by intersti-
tial inflammation and fibrosis, that clinicians discovered
the enlarged organs in association with renal dysfunction.
We were surprised to learn that most of the cysts
visible to the naked eye were no longer connected to
the tubules from which they derived [14]. It did not take
long for us to realize that the only way fluid could enter
these cysts was by net transepithelial secretion secondary
to solute transport, a finding that was in keeping with
our work on isolated tubule segments in vitro.
We then developed in vitro systems to examine some
of the regulatory mechanisms that might control the rate
at which cysts expand. Roberto Mangoo-Karim grew
Madin-Darby canine kidney (MDCK) cells and ADPKD
cyst mural epithelial cells within hydrated collagen gels
and as polarized monolayers on permeable supports and
determined that cyclic adenosine monophosphate (AMP)
was a potent cystogen [16, 17]. The nucleotide strikingly
increased the enlargement of MDCK and ADPKD mi-
crocysts and stimulated the transepithelial secretion of
fluid. There were hints in this early work that chloride
secretion might be important in driving fluid secretion
in response to cyclic AMP.
The obvious questions to be answered then centered
upon the cellular mechanisms of transepithelial solute
and fluid transport in renal cysts. Together with Min Ye,
Lawrence Sullivan, Darren Wallace, and many wonder-
ful faculty colleagues, graduate students, renal fellows,
and technical staff, we tested the hypothesis that epithe-
lial cells from human cysts could secrete solutes and
fluid. We examined this process directly by measuring
the amounts of fluid absorbed by or secreted into iso-
lated, intact cysts, dissected with amazing skill by Min
Ye, from kidneys that had been removed from patients
with PKD [18]. We found that forskolin, which activates
adenylyl cyclase, stimulated the secretion of fluid into
the cysts.
We determined that Na and Cl in isotonic propor-
tions were the major solutes secreted with the fluid
[19, 20]. When we added ouabain to the basolateral me-
dium, the secretion of fluid was inhibited [18, 19]. By
contrast, ouabain added to the cyst fluid did not block
secretion. These findings suggested that the functional
sodium pump was located within the basolateral mem-
brane, as it is in all normal renal tubules.
The cellular location of the alpha subunit of the Na
K, ATPase was confirmed by immunohistochemistry of
intact cysts and cultured monolayers of polarized human
cyst epithelial cells [21]. We also determined that the
cystic fibrosis transmembrane conductance regulator
(CFTR) was expressed within apical plama membranes
of cyst epithelial cells [21, 22]. These two proteins did not
colocalize, indicating that cyst epithelial cells maintained
normal polarity with respect to the major transporters
that might be involved in the secretion of Na, K, and
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Fig. 2. Mechanism by which cyclic adenosine monophosphate (AMP)
agonists stimulate the secretion of chloride and sodium into cysts. Chlo-
ride enters cells through the NKCC1 cotransporter and exits through
cystic fibrosis transmembrane conductance regulator (CFTR) channels
and purinergic chloride channels. Sodium enters the urine via a paracel-
lular pathway down an electrical potential gradient. Abbreviations are:
AVP, arginine vasopressin; ATP, adenosine triphosphate; cAMP, cyclic
adenosine monophosphate; PKA, protein kinase A.
Cl. Finding CFTR in renal cysts to this extent was a bit
of a surprise since a phenotype involving renal chloride
transport has never been convincingly detected in pa-
tients with cystic fibrosis.
With apologies to my colleagues, I will summarize a
decade of laboratory work aimed at understanding the
molecular basis of solute and fluid secretion in polycystic
kidneys (Fig. 2). As predicted, we found that the oua-
bain-sensitive sodium pump removed the cation from
within the cell, thereby creating a force for sodium to
enter the cell from the urine through the apical sodium
channel, ENaC. Potassium entering the cell via the so-
dium pump was returned to the blood through a channel
that could be inhibited by an array of compounds, includ-
ing barium and glibenclamide [23].
For the epithelium to secrete NaCl and fluid, we had
to find an anion transporter sufficiently powerful to over-
come the sodium absorption mechanism, something the
“sodium Mafia” believed just could not happen in renal
tubule cells. We were intrigued to find that the secretion
of NaCl and water depended upon the secondary active
transport of chloride from the blood into the urine [22,
24–28]. Chloride entered the cells through the NKCCl
cotransporter, leading to accumulation of the anion
within the cytoplasm to levels exceeding the electro-
chemical gradient driving sodium absorption from the
urine. ENaC appeared to be suppressed by the expres-
sion of CFTR, thereby facilitating the net movement
of chloride into the urine. The transepithelial voltage
remained lumen negative, thus favoring the selective
movement of sodium into the urine through a paracellu-
lar pathway. In this way, NaCl increased the solute con-
tent of the urine, setting up the osmotic flow of water into
the lumen through aquaporins in the respective plasma
membranes.
We have also learned that epithelial fluid secretion
may be regulated in renal cysts (Fig. 2). Eric Schwiebert
and Darren Wallace [29] found evidence of an apical
purinergic chloride transporter mechanism that operates
in parallel with CFTR. Upon the stimulation of cyclic
AMP production by a host of agonists, including arginine
vasopressin (AVP), prostaglandin E2 (PGE2), adenosine,
epinephrine, norepinephrine, and caffeine [30], there is
an increase in the traffic of chloride through the CFTR
and purinergic channels in the apical membrane. Sodium
enters the cyst cavity passively and water equilibrates
osmotically to complete the transportation of fluid into
the cyst.
One might wonder if chloride-dependent net fluid se-
cretion is merely a consequence of the cyst phenotype,
or do normal kidneys have this potential mechanism as
well? To our good fortune, Darren Wallace dared to
answer the question I had dodged two decades earlier.
He determined if normal mammalian collecting ducts
could secrete fluid. The answer to that question is a
resounding yes [31–33]! When he examined freshly iso-
lated, nonperfused inner medullary collecting ducts from
normal rats in vitro, he found that cyclic AMP and sev-
eral adenylyl cyclase agonists could stimulate the forma-
tion of lumens, similar to the observation that PAH
opened the lumens of nonperfused proximal straight tu-
bules (Fig. 1). Moreover, he showed that the solute and
fluid secretion process in normal collecting ducts de-
pended on the same transporters that were uncovered
in the cyst mural epithelial cells [33]. Thus, one of the
collateral benefits of studying cystic disease is that it led
to the discovery of a previously overlooked transport
process that could have a significant impact on the regu-
lation of salt and fluid balance by normal kidneys.
The evidence implicating a major role for cyclic AMP
in the acceleration of cyst filling with fluid was pretty
strong. But we wondered what effect this ubiquitous
nucleotide might have on the growth of the cells that
comprise the cyst wall? When Tamio Yamaguchi tackled
this question, most evidence had suggested that cyclic
AMP was antimitogenic in the kidney (i.e., it could slow,
not increase the rate of cell proliferation [34]). His initial
experiments in mural cells cultured from patients with
PKD produced some surprising results [35]. He found
that cyclic AMP did not inhibit, rather it stimulated the
proliferation of mural epithelial cells. Cyclic AMP and
forskolin increased the proliferation rate of polycystic
kidney cells to levels greater than the well-known mito-
gen, epidermal growth factor (EGF). Other cyclic AMP
agonists, such as secretin, vasoactive intestinal polypep-
tide, and PGE2, increased the rate of cell proliferation as
well. By contrast, the proliferation of cells from normal
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Fig. 3. Scheme by which adenylyl cyclase agonists promote cyst en-
largement by activating extracellular signal-regulated protein kinase
(ERK) and cystic fibrosis transmembrane conductance regulator
(CFTR) in a way that complements the action of receptor tyrosine
kinase agonists. See text for details. Abbreviations are: cAMP, cyclic
adenosine monophosphate; PKA, protein kinase A; MEK 1/2, mitogen-
activated kinase kinase.
human kidneys was inhibited by cyclic AMP agonists,
although they did proliferate in response to EGF and
fetal bovine serum.
Yamaguchi also explored the molecular mechanisms
involved in transducing growth factor signals to cyst cells
in polycystic kidneys. The activation by EGF of the mito-
gen-activated protein (MAP) kinase pathway in cyst epi-
thelial cells had been appreciated by others in the field
for several years. Yamaguchi confirmed that EGF, work-
ing through receptor tyrosine kinase, Raf-1, mitogen-
activated kinase kinase (MEK-1), and extracellular-reg-
ulated protein kinase (ERK) led to an increased rate of
cellular proliferation in cyst mural epithelial cells [35].
Shizuko Nagao found that phospho-ERK, the activated
form of MAP kinase, was expressed in those portions
of renal tubule epithelium that had been transformed
into the cyst phenotype [36]. The activated kinase was
expressed only in the cystic portions, supporting the view
that the MAP kinase pathway promoted the increased
proliferation of cyst epithelial cells.
Understanding how cyclic AMP might alter the growth
of cyst mural epithelial cells was more problematic than
EGF. We and others had supposed that cyclic AMP
might oppose the MAP kinase pathway at Raf-1 and
possibly serve to undermine the effect of EGF to stimu-
late the growth of cysts [34]. But, as published recently
[37], Yamaguchi and Nagao discovered that B-Raf, a
kinase that is ordinarily quiescent in normal kidney tu-
bules, is activated by cyclic AMP in PKD serving as a
bridge between PKA and MEK-1 (Fig. 3). It is possible,
then, that an increase in cyclic AMP from any one of
numerous agonists may lead to a sequence of intracellu-
lar changes that culminate in the activation of ERK,
thereby leading to an increase in mural cell division. It
is interesting to note that in this schema, the activation
of ERK by cyclic AMP is complementary to the activa-
tion of the MAP kinase pathway by EGF. Thus, cyclic
AMP has the potential to accelerate cyst enlargement
by stimulating the growth of the cells that line cyst walls
as well as by increasing the secretion of fluid into the
potential cavity created by that increased cell growth.
Clearly, these pathways are important targets for the
pharmacotherapy of PKD.
In recent work, Tamio Yamaguchi and James Calvet
have learned that the switching of B-Raf from a quies-
cent state to one that can be activated by cyclic AMP is
importantly controlled by the level of calcium within the
cells (abstract; J Am Soc Nephrol 13:105A, 2002). This
observation is of considerable importance for it ties the
MAP kinase and cyclic AMP pathways discussed here
with one of the primary functions of the polycystin pro-
teins, which is the regulation of intracellular calcium
levels.
EPILOGUE
Understanding the life-cycle of a renal cyst has been an
exciting journey, full of surprises. I think we understand
better where renal cysts come from, how they enlarge,
and what may make them grow faster. And, while ro-
mancing the cyst, we may have learned something new
about our own kidneys. Perhaps they are more like the
relatively uncomplicated, tubule-dominant kidneys of
ancient animals and arthropods than we might have
imagined. For they have retained the molecular mecha-
nisms to secrete fluid coupled to solute transport, a pro-
cess that appears to have been swept aside when the
glomerulus was upgraded several million years ago and
reabsorptive machinery was tacked onto renal tubules
to prevent the wasteful loss of salt and water [33]. Just
how those occult secretory mechanisms may affect the
function of normal mammalian kidneys is another mys-
tery begging to be solved (upon hearing this story, Barry
Brenner, M.D., called my attention to two research re-
ports in which collecting duct sodium secretion had curi-
ously surfaced in the course of experiments, but was not
pursued further [38, 39]).
I am confident that we will be hearing much more
about systems biology, the newest organizational para-
digm in science. Systems biology attempts to understand
how an organism works from an overall perspective, how
the components work together as a system. You know,
come to think of it, researchers in the renal field have
been practicing the discipline of systems biology for
nearly a century (after hearing the talk, Nathan Levin,
M.D., suggested the title should have been “A Cystems
Biology Approach”).
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